{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:51:27Z","timestamp":1768215087004,"version":"3.49.0"},"reference-count":42,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: Alcohol use disorder is a common condition with high morbidity and mortality and no highly effective treatments. Achieving and maintaining abstinence is necessary or desired for many persons with AUD, but is difficult due to the nature of the condition. Pharmacologic inhibition of the enzyme ALDH2, which increases levels of the substrate acetaldehyde when alcohol is imbibed, can serve as a powerful enforcer of efforts to remain abstinent. Disulfiram is an approved ALDH2 inhibitor via its active metabolite DETC-MeSO, but has many limitations, including numerous adverse effects, hepatotoxicity, oral administration, and unpredictable mechanistic activity. Methods: SOPH-110S, an analog of DETC-MeSO, was evaluated in a series of experiments to assess mechanism, pharmacokinetics in male beagle dogs, cardiovascular safety in telemeterized male beagle dogs, selectivity, off-target activity, CYP inhibition, and proof of mechanism in a rat model that included dosing and alcohol challenge followed by analysis of liver ALDH2 inhibition. Results: SOPH-110S showed high potency with a comparable IC50 vs. positive controls and no physiologically relevant off-target binding in an 84-target panel. It did not inhibit or induce any major CYP enzymes or meaningfully inhibit the hERG channel. After 10 days\u2019 dosing in rats, followed by administration of alcohol, SOPH-110S was a highly potent, dose-dependent inhibitor of ALDH2, comparable to DETC-MeSO. No cardiovascular safety concerns were found at multiples above expected clinical doses. Conclusions: The preclinical data support further clinical study of SOPH-110S as a potential ALDH2 inhibitor treatment for AUD. The FDA approved the IND to conduct a first-in-man phase 1 study in September 2025.<\/jats:p>","DOI":"10.3390\/cells15020123","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:30:34Z","timestamp":1768203034000},"page":"123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder: Preclinical Findings"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4291-8609","authenticated-orcid":false,"given":"Randall D.","family":"Marshall","sequence":"first","affiliation":[{"name":"Sophrosyne Pharmaceuticals Inc., 540 W. Madison Street, Suite 2500, Chicago, IL 60661, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Fowlie","sequence":"additional","affiliation":[{"name":"Sophrosyne Pharmaceuticals Inc., 540 W. Madison Street, Suite 2500, Chicago, IL 60661, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Sabouni","sequence":"additional","affiliation":[{"name":"Sophrosyne Pharmaceuticals Inc., 540 W. Madison Street, Suite 2500, Chicago, IL 60661, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders."},{"key":"ref_2","unstructured":"SAMHSA, and Center for Behavioral Health Statistics and Quality (2022). 2022 National Survey on Drug Use and Health."},{"key":"ref_3","unstructured":"SAMHSA Substance Abuse and Mental Health Services Administration (2024). Treatment Episode Data Set (TEDS) 2022: Ad-Missions to and Discharges from Substance Use Treatment Services Reported by Single State Agencies."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e236185","DOI":"10.1001\/jamanetworkopen.2023.6185","article-title":"Association Between Daily Alcohol Intake and Risk of All-Cause Mortality: A Systematic Review and Meta-Analyses","volume":"6","author":"Zhao","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0133","DOI":"10.1097\/HC9.0000000000000133","article-title":"Prevalence of Alcohol-Associated Liver Disease: A Systematic Review and Meta-Analysis","volume":"7","author":"Amonker","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Niu, X., Zhu, L., Xu, Y., Zhang, M., Hao, Y., Ma, L., Li, Y., and Xing, H. (2023). Global Prevalence, Incidence, and Outcomes of Alco-Hol-Related Liver Diseases: A Systematic Review and Meta-Analysis. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15749-x"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1017\/S0033291714002165","article-title":"The Heritability of Alcohol Use Disorders: A Meta-Analysis of Twin and Adoption Studies","volume":"45","author":"Verhulst","year":"2015","journal-title":"Psychol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.copsyc.2018.07.012","article-title":"Genetics of Alcohol Use Disorder: A Review","volume":"27","author":"Deak","year":"2019","journal-title":"Curr. Opin. Psychol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41588-018-0307-5","article-title":"Association Studies of up to 1.2 Million Individuals Yield New Insights into the Genetic Etiology of Tobacco and Alcohol Use","volume":"51","author":"Liu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41467-022-28735-5","article-title":"Associations between Alcohol Consumption and Gray and White Matter Volumes in the UK Biobank","volume":"13","author":"Daviet","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.35946\/arcr.v35.1.08","article-title":"Epigenetic Control of Gene Expression in the Alcoholic Brain","volume":"35","author":"Ponomarev","year":"2013","journal-title":"Alcohol Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","article-title":"The Neural Basis of Addiction: A Pathology of Motivation and Choice","volume":"162","author":"Kalivas","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.npp.1300295","article-title":"Differential Brain Activity in Alcoholics and Social Drinkers to Alcohol Cues: Relationship to Craving","volume":"29","author":"Myrick","year":"2004","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41386-020-00938-8","article-title":"Long-Term Alcohol Consumption Alters Dorsal Striatal Dopamine Release and Regulation by D2 Dopamine Receptors in Rhesus Macaques","volume":"46","author":"Salinas","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/B978-0-444-62619-6.00017-3","article-title":"Structural and Microstructural Imaging of the Brain in Alcohol Use Disorders","volume":"Volume 125","author":"Sullivan","year":"2014","journal-title":"Alcohol and the Nervous System"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/acer.12215","article-title":"Dominance of the Inactive Asian Variant over Activity and Protein Contents of Mitochondrial Aldehyde Dehydrogenase 2 in Human Liv-Er","volume":"38","author":"Lai","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of Medications for Alcohol Use Disorder in the US: Results from the 2019 National Survey on Drug Use and Health","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cpr.2005.11.005","article-title":"Relapse to Alcohol and Drug Use among Individuals Diagnosed with Co-Occurring Mental Health and Substance Use Disorders: A Review","volume":"26","author":"Bradizza","year":"2006","journal-title":"Clin. Psychol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-Analysis of Naltrexone and Acamprosate for Treating Alcohol Use Disorders: When Are These Medications Most Helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","article-title":"Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders","volume":"57","author":"Petrakis","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0006-2952(92)90555-W","article-title":"In Vitro and In Vivo Inhibition of Rat Liver Aldehyde Dehydrogenase by S-Methyl N,N-Diethylthiolcarbamate Sulfoxide, a New Metabolite of Disulfiram","volume":"43","author":"Hart","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1530-0277.1994.tb00023.x","article-title":"In Vivo Pharmacodynamic Studies of the Disulfiram Metabolite S-Methyl N,N-Diethylthiolcarbamate Sulfoxide: Inhibition of Liver Aldehyde Dehydrogenase","volume":"18","author":"Hart","year":"1994","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_25","unstructured":"(2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/15563650701636390","article-title":"Disulfiram Neuropathy: Two Cases of Distal Axonopathy","volume":"46","author":"Filosto","year":"2008","journal-title":"Clin. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An Improved Method to Correct the QT Interval of the Electrocardiogram for Changes in Heart Rate","volume":"22","author":"Water","year":"1989","journal-title":"J. Pharmacol. Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pst.454","article-title":"Review of the Statistical Analysis of the Dog Telemetry Study","volume":"10","author":"Aylott","year":"2011","journal-title":"Pharm. Stat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A Systematic Review of the Associations between Dose Regimens and Medication Com-Pliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0090-9556(25)06760-1","article-title":"Identification of the Human and Rat P450 Enzymes Responsible for the Sulfoxida-Tion of S-Methyl-N,N-Diethylthiocarbamate Sulfoxide (DETC-ME): The Terminal Step in the Bioactivation of Disulfiram","volume":"23","author":"Madan","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to Medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1176\/jnp.14.1.52","article-title":"Addiction Denial and Cognitive Dysfunction: A Preliminary Investigation","volume":"14","author":"Rinn","year":"2002","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"agaf001","DOI":"10.1093\/alcalc\/agaf001","article-title":"Preliminary Effects of Orl ANS-6637, an ALDH2 Inhibitor, on Cue-Induced Craving, Safety, and Alcohol Consumption among Adults with Alcohol Use Disorder: A Proof-of-Concept, Randomized, Human Laboratory Trial","volume":"60","author":"Miranda","year":"2025","journal-title":"Alcohol. Alcohol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1530-0277.2009.01031.x","article-title":"Suppression of Heavy Drinking and Alcohol Seeking by a Selective ALDH-2 Inhibitor","volume":"33","author":"Arolfo","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pbb.2009.09.004","article-title":"A Selective ALDH-2 Inhibitor Reduces Anxiety in Rats","volume":"94","author":"Overstreet","year":"2009","journal-title":"Pharmacol. Bio-Chem. Behav."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm.2200","article-title":"Inhibition of Aldehyde Dehydrogenase-2 Suppresses Cocaine Seeking by Generating THP, a Cocaine Use-Dependent Inhibitor of Dopamine Synthesis","volume":"16","author":"Yao","year":"2010","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic Advances from the Brain Disease Model of Addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_39","first-page":"754","article-title":"Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge","volume":"21","author":"Marcus","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients with Schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs. Daily Sublingual Buprenorphine with Naloxone for Treatment of Opioid Use Disorder","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200014050-00001","article-title":"Does Disulfiram Help to Prevent Relapse in Alcohol Abuse?","volume":"14","author":"Brewer","year":"2000","journal-title":"CNS Drugs"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/2\/123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:36:39Z","timestamp":1768203399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/2\/123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cells15020123"],"URL":"https:\/\/doi.org\/10.3390\/cells15020123","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}